{"version":"1.0","type":"link","title":"Retrospective evaluation of the \"neutrophil-lymphocyte ratio\" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.","author_name":"Mattioli C 외","author_url":"https://prs-insight.online/author/Mattioli%20C","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97388","thumbnail_width":1200,"thumbnail_height":630}